Uveitis associated with varicella virus vaccine

Bita Esmaeli-Gutstein; Jan Z. Winkelman

doi:10.1016/S0002-9394(99)00059-8

Uveitis associated with varicella virus vaccine

Bita Esmaeli-Gutstein, Jan Z. Winkelman

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

PURPOSE: To report a case of uveitis associated with the live attenuated varicella virus vaccine (Varivax; Merck and Co, Inc, West Point, Pennsylvania) in a young, otherwise healthy girl. METHODS: The time of onset of uveitis in relation to vaccination and the number and the pattern of distribution of vesicles were noted. The patient received oral acyclovir and topical steroids and cycloplegic drops. RESULTS: The uveitis and vesicular rash improved significantly after 7 days of treatment. A literature review and communications with the drug's manufacturer disclosed no identifiable previous cases of uveitis associated with Varivax. CONCLUSIONS: Uveitis should be recognized as a possible adverse side effect of the varicella vaccine.

Original language	English (US)
Pages (from-to)	733-734
Number of pages	2
Journal	American Journal of Ophthalmology
Volume	127
Issue number	6
DOIs	https://doi.org/10.1016/S0002-9394(99)00059-8
State	Published - Jun 1999

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0002-9394(99)00059-8

Cite this

@article{1ded320bca2c4bf48f3527302835f9a6,

title = "Uveitis associated with varicella virus vaccine",

abstract = "PURPOSE: To report a case of uveitis associated with the live attenuated varicella virus vaccine (Varivax; Merck and Co, Inc, West Point, Pennsylvania) in a young, otherwise healthy girl. METHODS: The time of onset of uveitis in relation to vaccination and the number and the pattern of distribution of vesicles were noted. The patient received oral acyclovir and topical steroids and cycloplegic drops. RESULTS: The uveitis and vesicular rash improved significantly after 7 days of treatment. A literature review and communications with the drug's manufacturer disclosed no identifiable previous cases of uveitis associated with Varivax. CONCLUSIONS: Uveitis should be recognized as a possible adverse side effect of the varicella vaccine.",

author = "Bita Esmaeli-Gutstein and Winkelman, \{Jan Z.\}",

year = "1999",

month = jun,

doi = "10.1016/S0002-9394(99)00059-8",

language = "English (US)",

volume = "127",

pages = "733--734",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Uveitis associated with varicella virus vaccine

AU - Esmaeli-Gutstein, Bita

AU - Winkelman, Jan Z.

PY - 1999/6

Y1 - 1999/6

N2 - PURPOSE: To report a case of uveitis associated with the live attenuated varicella virus vaccine (Varivax; Merck and Co, Inc, West Point, Pennsylvania) in a young, otherwise healthy girl. METHODS: The time of onset of uveitis in relation to vaccination and the number and the pattern of distribution of vesicles were noted. The patient received oral acyclovir and topical steroids and cycloplegic drops. RESULTS: The uveitis and vesicular rash improved significantly after 7 days of treatment. A literature review and communications with the drug's manufacturer disclosed no identifiable previous cases of uveitis associated with Varivax. CONCLUSIONS: Uveitis should be recognized as a possible adverse side effect of the varicella vaccine.

AB - PURPOSE: To report a case of uveitis associated with the live attenuated varicella virus vaccine (Varivax; Merck and Co, Inc, West Point, Pennsylvania) in a young, otherwise healthy girl. METHODS: The time of onset of uveitis in relation to vaccination and the number and the pattern of distribution of vesicles were noted. The patient received oral acyclovir and topical steroids and cycloplegic drops. RESULTS: The uveitis and vesicular rash improved significantly after 7 days of treatment. A literature review and communications with the drug's manufacturer disclosed no identifiable previous cases of uveitis associated with Varivax. CONCLUSIONS: Uveitis should be recognized as a possible adverse side effect of the varicella vaccine.

UR - https://www.scopus.com/pages/publications/0033037837

UR - https://www.scopus.com/inward/citedby.url?scp=0033037837&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(99)00059-8

DO - 10.1016/S0002-9394(99)00059-8

M3 - Article

C2 - 10372892

AN - SCOPUS:0033037837

SN - 0002-9394

VL - 127

SP - 733

EP - 734

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

IS - 6

ER -

Uveitis associated with varicella virus vaccine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this